Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial

Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial

The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non‐small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this pha...

Full description

Bibliographic Details
Main Authors: Henrik Horndalsveen, Tine Norman Alver, Astrid Marie Dalsgaard, Lotte Victoria Rogg, Nina Helbekkmo, Bjørn Henning Grønberg, Tarje Onsøien Halvorsen, Christina Ramberg, Vilde Drageset Haakensen, Åsa Kristina Öjlert, Maria Moksnes Bjaanæs, Åslaug Helland
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Molecular Oncology
Subjects:
circulating tumour DNA
immunotherapy
liquid biopsy
NSCLC
radiotherapy
Online Access:https://doi.org/10.1002/1878-0261.13330

Internet

https://doi.org/10.1002/1878-0261.13330

Similar Items